Trial Name: Adventrx 510-05
A Phase III Multi-Center, Randomized Clinical Trial to Evaluate the Safety and Efficacy of Cofactor and 5-FU plus Bevacizumab vs. Leucovorin and 5-FU plus Bevacizumab as Initial Treatment for Metastatic Colorectal Cancer
Trial Description:
The purpose of this trial is to find out how well patients with metastatic colon or rectal cancer respond to 5-FU and cofactor plus bevacizumab when compared to the standard treatment of 5-FU and leucovorin plus bevacizumab.
Treatment Plan:
Patients will be randomized to one of two treatment groups:
Group 1 - 5-FU, cofactor plus bevacizumab
Group 2 - 5-FU, leucovorin plus bevacizumab
Patients:
- 18 years of age or older
- Surgically incurable metastatic colon or rectal cancer
- No prior chemotherapy or radiation therapy for this diagnosis
- No brain metastasis
- Labs tests, a current physical exam and medical history must meet study specific criteria
This is a brief overview of this clinical trial and only selected eligibility criteria are listed.
If you are interested in receiving more information to see if you are eligible for this study, please contact:
Mercy General Hospital, Rhoda Pineda at (916) 453-4651, or e-mail rpineda@chw.edu
Mercy San Juan Medical Center, Margaret Murphy at (916) 537-5109, or e-mail margaret.murphy2@chw.edu
